MENU
JUN 17, 2020 12:00 PM PDT

Panel discussion: Critical design considerations for COVID-19 rapid POC diagnostic test development

Speakers
  • Global Technology Lead, Diagnostics, Cytiva
    Biography

      Dr. Hochleitner is a cell and molecular biologist and has covered different roles in the field of membrane research and development, and developing diagnostic tests on solid surfaces. He is working in the field of lateral flow tests for more than 25 years.

    • President and Co-Founder, DCN Diagnostics
      Biography
        Dr O'Farrell has worked in the rapid diagnostics field for over 25 years and has been involved in over 200 product development programs in that time. He has wide experience in the development, manufacturing and commercialization of rapid diagnostics in a variety of industry verticals. In 2005 he co-founded DCN Diagnostics, a market leading provider of contract development and manufacturing services to the rapid diagnostics business, where is holds the role of President.
      • President and CEO, Sona Nanotech
        Biography
          A commercially-minded scientist, Darren joined Sona after 14 years' experience in the diagnostic and nanoparticle industry. He previously worked for one of the leading providers of technologies to the global diagnostics market, where he specialised in product manufacture and development in the area of noble metal nanoparticles and lateral flow diagnostics. Darren is a key opinion leader at industry seminars and conferences and acts as an advisory board member to the World Gold Council. Darren has a BSC in Biomedical Science and Toxicology from University of Wales Institute Cardiff and a Master of Business Administration from University of Bath.
        • Commercial Director, Diagnostics, Avacta Life Sciences
          Biography
            David brings to Avacta over 25 years international experience in business development, marketing and sales management in the in-vitro diagnostic medical devices industry, having held senior commercial and Board level positions in global corporations, angel and venture capital funded start-ups and a sector specific trade association. He is currently a Board member for two early-stage diagnostic businesses developing novel point of care diagnostic testing platforms, and has served on the Executive Committee of the British In Vitro Diagnostics Association (BIVDA). David has a BSc (Hons) in Biochemistry and Microbiology from the University of St. Andrews and a MBA from the Open University Business School.
          • Senior Product Leader, Cytiva
            Biography

              Part of the Senior Management team within the Whatman business area of Cytiva, with overall responsibility for the performance of a large portfolio of products and services, primarily focused on the diagnostic rapid testing market. Experience of involvement with diagnostic development companies for over 5 years and part of the Cytiva (formerly GE Life Sciences) business for over 9 years.


            Abstract

            The spread of the SARS-COV-2 (COVID-19) pandemic is driving an urgent need for extensive testing, in order to quickly and accurately assess both who is infected, and who has been infected. In order to reach the scale of testing needed, a dual approach of both reverse transcription polymerase chain reaction (RT-PCR) molecular tests and lateral flow based tests needs to be implemented. This session will discuss the design challenges encountered during COVID-19 rapid point of care (POC) diagnostic test development, and the solutions that exist to overcome them.

            Learning Objectives:

            1. Understand current COVID-19 diagnostic technologies

            2. Why a dual approach of both RT-PCR and lateral flow based tests is needed

            3. Design challenges you need to be aware of when developing a COVID-19 lateral flow test

            4. What support exists to help developers overcome design challenges


            Show Resources
            You May Also Like
            SEP 10, 2020 9:00 AM PDT
            C.E. CREDITS
            SEP 10, 2020 9:00 AM PDT
            Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
            C.E. CREDITS
            This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
            JUN 17, 2020 1:30 PM PDT
            C.E. CREDITS
            JUN 17, 2020 1:30 PM PDT
            Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
            NOV 18, 2020 8:00 AM PST
            Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
            C.E. CREDITS
            NOV 18, 2020 8:00 AM PST
            Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
            DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
            JUN 09, 2020 10:00 AM PDT
            C.E. CREDITS
            JUN 09, 2020 10:00 AM PDT
            DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
            SEP 17, 2020 2:00 PM PDT
            C.E. CREDITS
            SEP 17, 2020 2:00 PM PDT
            Learning Objectives: 1. Understanding the integral value of collaboration for advancement in scientific research; how to establish and grow academic, Pharma, and industry connections 2. Lear...
            Loading Comments...
            Show Resources
            Attendees
            • See more